Board of Directors

Kenneth B. Lee, Jr.

Board Chairman & General Partner at Hatteras Venture Partners

Ken is a general partner for HPV III at Hatteras Venture Partners and is involved in deal sourcing, investment decisions and implementing exit strategies. He is also a general partner for HVP II, where he has played an important role in deal sourcing, syndication and management recruitment, and evaluation.

Full Bio

Jeff Williams

Chief Executive Officer

Jeff co-founded Clinipace Worldwide in 2003 with the idea of building a clinical research company that would take a different approach to managing clinical trials. He wanted to build a company where technology served as the foundation of the research. At Clinipace Worldwide, technology is in our DNA with Jeff and his team successfully delivering a technology-amplified approach to conducting research resulting in strong year-over-year growth.

Full Bio

Brian C. Carney

Principal, Harbert Management Corporation (HMC)

Brian C. Carney is a Principal in the General Partner. Mr. Carney joined HMC in 2007 and currently serves on the boards of Clinipace Worldwide, OpenQ, and Privaris. Mr. Carney is also a board observer for Intelliject, JackBe, nContact, and PeopleMatter. 

Full Bio

John Crumpler

General Partner at Hatteras Venture Partners

John co-founded Hatteras Venture Partners in 2000 after a successful career as a technology entrepreneur. At Hatteras, John is a General Partner and is responsible for the firm's investments in health care and life science information technology, and overall fund operations.

Full Bio

Melissa Daniels

Managing Principal at Morgan Stanley Expansion Capital & the Co-Head and Managing Member of Morgan Stanley Venture Partners

Melissa is a Managing Principal at Morgan Stanley Expansion Capital and the Co-Head and Managing Member of Morgan Stanley Venture Partners. Melissa has been an active growth equity investor and board member in numerous software, healthcare service, healthcare IT and medical device companies.

Full Bio

Julia P. Gregory

Executive Vice President and Chief Financial Officer at ContraFect Corporation

Ms. Gregory is an executive vice president and chief financial officer at ContraFect Corporation. ContraFect, a New York-based biotechnology company, is committed to developing technologies, treatments, and products that will target and kill the most virulent and resistant microorganisms—including gram-positive bacteria, such as Staphylococcus (MRSA), and viruses, such as Influenza.

Full Bio

Jeremy Mario

Principal, Private Equity Investments for Mario Family Partners

Jeremy serves as Principal, Private Equity Investments for Mario Family Partners and has more than ten years experience in the pharmaceutical and health care fields, ranging from clinical development services to marketing and research.

Full Bio

Gena Reed

Former CEO at Paragon Biomedical

Gena co-founded Paragon Biomedical with her late husband Nick Reed in 1989. Together with their management team they built Paragon Biomedical into a global CRO employing more than 240 employees, contractors, and consultants prior to its acquisition by Clinipace Worldwide. With the acquisition Gena joins the Clinipace Board.

Full Bio

Clinipace Worldwide
© 2013 CLINIPACE. All Rights Reserved. Website Privacy Statement | US-EU Safe Harbor | eLinks